Clinical Trials

Phase I/II Study of CD5 CAR Engineered IL15-Transduced Cord Blood-Derived NK Cells in Conjunction with Lymphodepleting Chemotherapy for the Management of Relapsed/Refractory Hematological Malignances

Link to more information on ClinicalTrials.gov Opens a new window

PI: Chitra Hosing, M.D

Phase I/II study of CAR.70- engineered IL15-transduced cord blood-derived NK cells in conjunction with lymphodepleting chemotherapy for the management of relapse/refractory hematological malignances

Link to more information on ClinicalTrials.gov Opens a new window

PI: David Marin, M.D.

Modified Immune Cells (AFM13-NK) and A Monoclonal Antibody (AFM13) in Treating Patients With Recurrent or Refractory CD30 Positive Hodgkin or Non-Hodgkin Lymphomas

Link to more information on ClinicalTrials.gov Opens a new window

PI: Yago Nieto, M.D.

Phase II Study Assessing the Effect of BK Specific CTL Lines Generated by Ex Vivo Expansion in Stem Cell Transplant Recipients with BK Infection and JC Virus Infection

Link to more information on ClinicalTrials.gov Opens a new window

PI: Amanda Olson, M.D.

Most Closely HLA Matched Allogeneic CMV Specific Cytotoxic T-Lymphocytes (CTL) to Treat CMV Infection after Hemapoietic Stem Cell Transplantation (HSCT)

Link to more information on ClinicalTrials.gov Opens a new window

PI: Betul Oran, M.D.

Phase I/II Trial of Cord blood-derived NK cells genetically engineered with NY-ESO-1 TCR/IL-15 cell receptor for relapsed/refractory multiple myeloma

Link to more information on ClinicalTrials.gov Opens a new window

PI: Muzaffar Qazilbash, M.D.

Phase I/II Study of Engineered T Cell Receptor-Modified NK Cells Targeting PRAME in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Myeloid Malignancies

Link to more information on ClinicalTrials.gov Opens a new window

PI: Jeremy Ramdial, M.D.

Administration of Off-the-Shelf, Expanded, Most Closely HLA Matched, Third Party Viral Specific T Cells for Therapy of Adenovirus Related Disease in Immunocompromised Patients

Link to more information on ClinicalTrials.gov Opens a new window

PI: David Marin, M.D.

Phase 1 Dose Escalation and Expansion Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Patients with Advanced Solid Tumors (TROPIKANA)

Link to more information about this trial on breast and lung cancers on ClinicalTrials.gov

PI: Ecaterina Dumbrava, M.D.

Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and Young Adults With Relapsed or Refractory Solid Tumors

Link to more information on ClinicalTrials.gov Opens a new window

PI: Demetrios Petropoulos, M.D.

Phase I/II Clinical Trial of Autologous CMV-Specific Cytotoxic T Cells for GBM Patients

Link to more information on ClinicalTrials.gov Opens a new window

PI: Shiao-Pei Weathers, M.D.

A Phase I clinical trial with a window-of-opportunity component of engineered NK cells containing deleted TGF-ßR2 and NR3C1 in recurrent grade 4 astrocytoma (glioblastoma)

Link to more information on ClinicalTrials.gov Opens a new window

PI: Shiao-Pei Weathers, M.D.

A Phase 1b Study of Immunotherapy with ex vivo Pre-Activated and expanded CB-NK cells in combination with Cetuximab, in colorectal cancer patients with minimal residual disease (MRD)

Link to more information on ClinicalTrials.gov Opens a new window

PI: Maria Morelli, M.D.

Study Assessing the Feasibility, Safety and Efficacy of Genetically Engineered Glucocorticoid Receptor Knock Out Virus Specific CTL Lines for Viral Infections in Immunosuppressed Cancer Patients

Link to more information on ClinicalTrials.gov Opens a new window

PI: May Daher, M.D.

Phase 1 Dose Escalation and Expansion Study of PRAME T Cell Receptor (TCR) Engineered NK Cells in Participants With Recurrent and/or Refractory Melanoma (PRAMETIME-Mel)

Link to more information on ClinicalTrials.gov Opens a new window

PI: Adi Diab, M.D.

Phase I/II study of CAR.70-engineered IL15-transduced cord blood-derived NK cells in conjunction with lymphodepleting chemotherapy for the management of advanced renal cell carcinoma, mesothelioma and osteosarcoma

Link to more information on ClinicalTrials.gov Opens a new window

PI: David Hong, M.D.

AD-PluReceptor plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients with Autoimmune Disorders

Link to more information on ClinicalTrials.gov Opens a new window

PI: Chitra Hosing, M.D.

Phase I/II study of TROP2 CAR engineered IL15-transduced cord blood-derived NK cells delivered intraperitoneally for the management of platinum resistant ovarian cancer, mesonephric-like adenocarcinoma, and pancreatic cancer

Link to more information on ClinicalTrials.gov Opens a new window

PI: Amir Jazaeri, M.D.

Phase I/Ib study of adoptive NK expressing an affinity-enhanced T-cell receptor (TCR) reactive against the NY-ESO-1

Link to more information on ClinicalTrials.gov Opens a new window

PI: Andrew Livingston, M.D.

Administration of Expanded, Most Closely HLA Matched SARS-CoV-2-Specific T Cells for the Treatment of COVID-19 in Patients with Cancer

Link to more information on ClinicalTrials.gov Opens a new window

PI: David Marin, M.D.